)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Cantargia (CANTA) investor relations material
Cantargia Investing in Life Science 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investing in Life Science 2025 summary25 Sep, 2025
Strategic and operational updates
Newly appointed CEO presented recent operational and strategic progress, emphasizing a focus on IL-one RAP antibody development and platform expansion.
Lead asset nadunolumab has shown strong clinical effects in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer, with over 300 patients treated.
A transformative partnership with Otsuka, announced in July, validated the technology and provided financial flexibility for expanded activities.
The company is advancing a Phase 2b/3-ready product for PDAC and developing bispecific and ADC platform assets.
The management team brings comprehensive industry experience to support these initiatives.
Clinical and scientific highlights
Nadunolumab targets IL-one RAP, blocking cytokine production and labeling tumor cells for immune destruction.
High IL-one RAP expression is linked to poor prognosis; targeting these patients with nadunolumab improved mean overall survival to 14 months versus 10.4 months for low expression and 9 months historically.
60% of advanced metastatic PDAC patients have high IL-one RAP, representing the primary target population.
A prognostic marker for high IL-one RAP has completed feasibility and is in validation, enabling patient selection for upcoming trials.
Planned randomized controlled trial will focus on high IL-one RAP metastatic PDAC patients, with overall survival as the primary endpoint.
Financial and partnership developments
The Otsuka deal included a $33 million upfront payment, with additional development, regulatory, and sales milestones, plus high single-digit to low double-digit royalties.
The partnership provides resources to further develop nadunolumab and invest in the IL-one RAP platform.
CEO brings experience from major deals and financing rounds, leveraging a broad network to support future funding.
Active efforts in investor and public relations aim to increase market interest.
Regulatory plan for PDAC prognostic marker?
Breakdown Otsuka deal milestones
Timeline for TRI-four OS data?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Cantargia earnings date
Q3 202519 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Cantargia AB, a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. Its lead product is CAN04, an antibody directed the interleukin-1 receptor accessory protein that targets cancer cells that express IL1RAP on their surface; and CAN04 is currently being developed in two clinical programs, one focusing on treatment of lung cancer and another on treatment of pancreatic cancer. Cantargia AB was founded in 2010 and is based in Lund, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage